Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
NCT05962229Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicotine in nicotine dependence (3 arms), sponsored by University of California, San Francisco. Primary endpoint: Mean Nicotine Exposure Over Time at 7 hours. Started Dec 2024; status: recruiting.
02
Drugs
nicotine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT05962229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962229.